A study on SerpinPC for patients with severe hemophilia A or moderately severe to severe hemophilia B was terminated due to a business and strategic decision.
1 Discontinued Research Program
All entries for: ApcinteX
November 14, 2024
ApcinteX
Discontinued Research
United Kingdom
1-50 employees
Disease Area: Rare Diseases
Drug Type: Small Molecule
